Interestingly, combinations involving anti-PD-1/PD-L1 with either chemotherapy or vascular endothelial growth factor (VEGF) inhibitors may actually have a slightly lower incidence of pneumonitis, although these regimens have generally not been directly compared with anti-PD-1 monotherapy. Here, VEGFA is linked to pneumonitis.